Antinociceptive activity of and clinical experience with buprenorphine in swine

Citation
Na. Rodriguez et al., Antinociceptive activity of and clinical experience with buprenorphine in swine, CONT T LAB, 40(3), 2001, pp. 17-20
Citations number
14
Categorie Soggetti
Animal Sciences
Journal title
CONTEMPORARY TOPICS IN LABORATORY ANIMAL SCIENCE
ISSN journal
10600558 → ACNP
Volume
40
Issue
3
Year of publication
2001
Pages
17 - 20
Database
ISI
SICI code
1060-0558(200105)40:3<17:AAOACE>2.0.ZU;2-0
Abstract
We performed antinociceptive testing on swine receiving buprenorphine. Intr avenous access was achieved, and animals were allowed to recover for 24 h. Baseline skin-twitch latency to a focused light source was determined for e ach animal. Animals received intravenous (i.v.) buprenorphine at 0.08 (n = 1), 0.16 (n = 1), 0.005 (n = 5), 0.01 (n = 5), or 0.02 mg/kg (n = 6). Skin- twitch latency was determined 15, 30, 60, 120, 180, 240, 300, 360, 420, 480 , 540, and 600 min after buprenorphine administration. Analgesic activity a s measured by a significant increase in latency time over baseline values o ccurred at all time points except 480 min in animals that received 0.02 mg/ kg buprenorphine i.v. Analgesic activity to 420 min was demonstrated in ani mals that received 0.01 mg/kg buprenorphine i.v. Analgesic activity was not demonstrated at any time paint in animals that received 0.005 mg/kg bupren orphine i.v. A retrospective analysis of postoperative care records was per formed to determine whether 0.01 mg/kg buprenorphine i.v. or intramuscularl y (i.m.) postoperatively to swine provided clinically relevant analgesia. R ecords of swine receiving buprenorphine from 1997 to 2000 were reviewed for indications of treatment failure, such as pain or a change in analgesic re gimen from that used routinely. Treatment Failure occurred in 18 of 416 (4. 3%) cases treated with buprenorphine. This failure occurred in 17% of cases with problems categorized as inflammatory in nature and in 15.5% of those with systemic problems or organ failure. We concluded that antinociceptive testing predicted that buprenorphine administered at 0.01 mg/kg i.v. in swi ne likely would provide analgesic efficacy for 6 h and when administered at 0.02 mg/kg i.v. likely would provide 10 h analgesia. Clinical signs of pai n in animals recovering from surgery were not observed in the majority of c ases when buprenorphine was administered twice or thrice daily at 0.01 mg/k g i.m. or i.v. However, buprenorphine was less effective at treating signs of pain associated with inflammation, organ failure, or systemic disease th an at ameliorating pain associated,vith surgical incisions and orthopedic, dental, and ophthalmic procedures.